Publication
Article Metrics
Citations
Online attention
Expanding the biocatalytic toolbox: A singular P450 enzyme efficiently produces diverse pharmaceutical metabolites
Authors:
Laura N.
Jeffreys
(University of Manchester)
,
Sian
Thistlethwaite
(University of Manchester)
,
Matthew J.
Cliff
(University of Manchester)
,
Harshwardhan
Poddar
(University of Manchester)
,
Sahara
Bhanot
(University of Manchester)
,
Richard B.
Tunnicliffe
(University of Manchester)
,
Marina
Golovanova
(University of Manchester)
,
Katherine
Hollywood
(University of Manchester)
,
Colin W.
Levy
(University of Manchester)
,
Michael W.
Voice
(Cypex Ltd)
,
David
Leys
(University of Manchester)
,
Kirsty J.
Mclean
(University of Huddersfield)
,
Jonathan P.
Waltho
(University of Manchester; University of Sheffield)
,
Andrew W.
Munro
(University of Manchester)
,
Hazel M.
Girvan
(University of Huddersfield)
Co-authored by industrial partner:
Yes
Type:
Journal Paper
Journal:
Acs Omega
, VOL 297
State:
Published (Approved)
Published:
August 2026
Diamond Proposal Number(s):
17773
,
24447
Open Access
Abstract: P450 BM3 is a natural fusion protein with a P450 domain fused to its necessary redox partner and capable of binding a range of fatty acids at high catalytic rates. The flexibility of the active site and catalytic efficiency have led to extensive research aimed at modifying substrate and product profiles for its utilization as a biocatalyst. The introduction of a double mutation (DM) at the base of the active site (A82F/F87V) allows the binding of a broad range of structurally diverse small molecules, including pharmaceutical drugs. Herein, we describe screening with an FDA-approved drug compound library, and the results exhibit the promiscuous nature of the DM BM3 variant. Of the 978 compounds screened; 59% of the library elicited UV–vis spectral shifts indicative of binding with a range of structurally diverse drugs. The interaction of the DM BM3 variant with a range of structurally diverse drugs, with a particular focus on the antidiabetic glitazone (thiazolidinedione) class, was investigated to observe ligand binding modes and metabolite production. BM3-derived metabolites were successfully produced and structurally elucidated for several structurally diverse drugs in the steroid, glitazone, meglitinide, terpene lactone, retinoid, and fibrate classes. The range of modifications performed includes some that are human P450-derived metabolites. Structural elucidation of the troglitazone-bound DM variant P450 domain shows an unusually close crystallographic interaction between the substrate and heme cofactor. We report here the use of the DM BM3 variant as a model for the main human metabolizing P450 enzymes CYP1A1, CYP2B6, CYP2C8, CYP2C9, and CYP3A4, as well as a biotechnological tool for the production of metabolites with diverse functionality.
Diamond Keywords: Enzymes
Subject Areas:
Biology and Bio-materials,
Chemistry,
Medicine
Instruments:
I03-Macromolecular Crystallography
,
I04-1-Macromolecular Crystallography (fixed wavelength)
,
I04-Macromolecular Crystallography
Added On:
17/08/2026 08:24
Documents:
acsomega.6c01534.pdf
Discipline Tags:
Biotechnology
Biochemistry
Catalysis
Chemistry
Structural biology
Life Sciences & Biotech
Technical Tags:
Diffraction
Macromolecular Crystallography (MX)
